MedPath
HSA Approval

XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 300MG/2.0ML

SIN17029P

XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 300MG/2.0ML

XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 300MG/2.0ML

June 21, 2024

NOVARTIS (SINGAPORE) PTE LTD

Regulatory Information

NOVARTIS (SINGAPORE) PTE LTD

Therapeutic

Prescription Only

Formulation Information

INJECTION, SOLUTION

SUBCUTANEOUS

Medical Information

R03DX05

Manufacturer Information

NOVARTIS (SINGAPORE) PTE LTD

Novartis Pharma Stein AG

Active Ingredients

Omalizumab

300.00 mg/2.0 mL

Omalizumab

Documents

Package Inserts

Xolair PI.pdf

Approved: June 21, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 300MG/2.0ML - HSA Approval | MedPath